Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8120827 | 0.72 | ALDH1A1 (0.52) | MCL1ALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL2070927 | 0.69 | IDO1 (0.44) | ALDH1A1HTTSMN1; SMN2LMNATSHR | |
| SCHEMBL8602545 | 0.67 | HTR6 (0.56) | ALDH1A1HTTSMN1; SMN2POLBGLA | |
| SCHEMBL29094155 | 0.67 | CYP1A2 (0.41) | ALDH1A1SMN1; SMN2POLBTSHRMAPT | |
| Hydrochloric Acid SCHEMBL30989178 | 0.66 | HTR6 (0.55) | ALDH1A1HTTSMN1; SMN2POLBGLA | |
| SCHEMBL8112005 | 0.65 | MCL1 (0.68) | MCL1ALDH1A1 | |
| SCHEMBL9352499 | 0.65 | LDHA (0.61) | MCL1ALDH1A1HTTSMN1; SMN2KMT2A | |
| SCHEMBL17441840 | 0.65 | POLB (0.51) | MCL1ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL9276192 | 0.65 | CHEK1 (0.48) | MCL1ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL8356540 | 0.64 | MCL1 (0.56) | MCL1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534793-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2009-05-19 | — | — | US | claimed |
| EP-1305308-B1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2006-12-20 | — | — | EP | claimed |
| US-7534793-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2009-05-19 | — | — | US | disclosed |
| EP-1305308-B1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20060014749-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. | 2006-01-19 | — | — | US | disclosed |
| US-6962917-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014749-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | AZI2, NPEPPS, AMPD2 | MCL1 463/4885ALDH1A1 1016/4885HTT 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.